Research Article|Articles in Press

Elevated preoperative serum interleukin-6 level is predictive for worse postoperative outcome after soft tissue sarcoma surgery



      The pro-inflammatory cytokine interleukin-6 (IL-6) plays a role in cancer development and progression, but research into the predictive value of IL-6 on postoperative outcome in soft tissue sarcoma (STS) is scarce. The purpose of this study is to investigate the predictive value of serum IL-6 level for the achievement of assumed (post)operative outcome after STS surgery, the so-called textbook outcome.


      Preoperative IL-6 serum levels were collected in all patients with a STS at first presentation between February 2020 and November 2021. Textbook outcome was defined as a R0 resection, no complications, no blood transfusions, no reoperation within the postoperative period, no prolonged hospital stay, no hospital readmission within 90-days, and no mortality within 90-days. Factors associated with textbook outcome were determined by multivariable analysis.


      Among 118 patients with primary, non-metastatic STS, 35.6% achieved a textbook outcome. Univariate analysis showed that smaller tumor size (p = 0.026), lower tumor grade (p = 0.006), normal hemoglobin (Hb, p = 0.044), normal white blood cell (WBC) count (p = 0.018), normal C-reactive protein (CRP) serum level (p = 0.002) and normal IL-6 serum level (p = 1.5 × 10−5) were associated with achieving textbook outcome after surgery. Multivariable analysis showed that elevated IL-6 serum level (p = 0.012) was significantly associated with not achieving a textbook outcome.


      Increased IL-6 serum level is predictive for not achieving a textbook outcome after surgery for primary, non-metastatic STS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • WHO Classification of Tumours Editorial Board
        WHO classification of tumours of soft tissue and bone.
        fifth ed. IARC Press, 2020
        • Mantovani A.
        • Allavena P.
        • Sica A.
        • Balkwill F.
        Cancer-related inflammation.
        Nature. Jul 24 2008; 454: 436-444
        • Grivennikov S.I.
        • Greten F.R.
        • Karin M.
        Immunity, inflammation, and cancer.
        Cell. Mar 19. 2010; 140: 883-899
        • Faria S.S.
        • Fernandes Jr., P.C.
        • Silva M.J.
        • et al.
        The neutrophil-to-lymphocyte ratio: a narrative review.
        Ecancermedicalscience. 2016; 10: 702
        • Zhou X.
        • Du Y.
        • Huang Z.
        • et al.
        Prognostic value of PLR in various cancers: a meta-analysis.
        PLoS One. 2014; 9e101119
        • McMillan D.C.
        Systemic inflammation, nutritional status and survival in patients with cancer.
        Curr Opin Clin Nutr Metab Care. May 2009; 12: 223-226
        • Hunter C.A.
        • Jones S.A.
        IL-6 as a keystone cytokine in health and disease.
        Nat Immunol. 2015; 16 (May): 448-457
        • Kishimoto T.
        IL-6: from its discovery to clinical applications.
        Int Immunol. May 2010; 22: 347-352
        • Jones S.A.
        • Jenkins B.J.
        Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.
        Nat Rev Immunol. Dec 2018; 18: 773-789
        • Kumari N.
        • Dwarakanath B.S.
        • Das A.
        • Bhatt A.N.
        Role of interleukin-6 in cancer progression and therapeutic resistance.
        Tumour Biol. 2016; 37 (Sep): 11553-11572
        • Balkwill F.
        • Mantovani A.
        Inflammation and cancer: back to Virchow?.
        Lancet. 2001; 357: 539-545
        • Johnson D.E.
        • O'Keefe R.A.
        • Grandis J.R.
        Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
        Nat Rev Clin Oncol. 2018; 15 (Apr): 234-248
        • Grivennikov S.
        • Karin M.
        Autocrine IL-6 signaling: a key event in tumorigenesis?.
        Cancer Cell. 2008; 13 (Jan): 7-9
        • Silva E.M.
        • Mariano V.S.
        • Pastrez P.R.A.
        • et al.
        High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer.
        PLoS One. 2017; 12e0181125
        • Cai C.
        • Peng X.
        • Zhang Y.
        Serum IL-6 level predicts the prognosis and diagnosis in cervical cancer patients.
        Int J Womens Health. 2022; 14: 655-663
        • Salgado R.
        • Junius S.
        • Benoy I.
        • et al.
        Circulating interleukin-6 predicts survival in patients with metastatic breast cancer.
        Int J Cancer. 2003; 103 (Feb 20): 642-646
        • Knüpfer H.
        • Preiss R.
        Serum interleukin-6 levels in colorectal cancer patients--a summary of published results.
        Int J Colorectal Dis. 2010; 25 (Feb): 135-140
        • Szczepanik A.M.
        • Scislo L.
        • Scully T.
        • et al.
        IL-6 serum levels predict postoperative morbidity in gastric cancer patients.
        Gastric Cancer. Aug 2011; 14: 266-273
        • Nguyen D.P.
        • Li J.
        • Tewari A.K.
        Inflammation and prostate cancer: the role of interleukin 6 (IL-6).
        BJU Int. 2014; 113 (Jun): 986-992
        • Browning L.
        • Patel M.R.
        • Horvath E.B.
        • Tawara K.
        • Jorcyk C.L.
        IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis.
        Cancer Manag Res. 2018; 10: 6685-6693
        • Hagi T.
        • Nakamura T.
        • Iino T.
        • et al.
        The diagnostic and prognostic value of interleukin-6 in patients with soft tissue sarcomas.
        Sci Rep. Aug 29 2017; 7: 9640
        • Rutkowski P.
        • Kaminska J.
        • Kowalska M.
        • Ruka W.
        • Steffen J.
        Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis.
        Int J Cancer. Aug 1 2002; 100: 463-471
        • Busweiler L.A.
        • Schouwenburg M.G.
        • van Berge Henegouwen M.I.
        • et al.
        Textbook outcome as a composite measure in oesophagogastric cancer surgery.
        Br J Surg. May 2017; 104: 742-750
        • Heidsma C.M.
        • Hyer M.
        • Tsilimigras D.I.
        • et al.
        Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: results of the US Neuroendocrine Tumor Study Group.
        J Surg Oncol. 2020; 121 (Jun): 1201-1208
        • Kalff M.C.
        • Vesseur I.
        • Eshuis W.J.
        • et al.
        The association of textbook outcome and long-term survival after esophagectomy for esophageal cancer.
        Ann Thorac Surg. Oct 2021; 112: 1134-1141
        • Levy J.
        • Gupta V.
        • Amirazodi E.
        • et al.
        Textbook outcome and survival in patients with gastric cancer: an analysis of the population registry of esophageal and stomach tumours in ontario (PRESTO).
        Ann Surg. Jan 1 2022; 275: 140-148
        • Ten Berge M.G.
        • Beck N.
        • Steup W.H.
        • et al.
        Textbook outcome as a composite outcome measure in non-small-cell lung cancer surgery.
        Eur J Cardio Thorac Surg. Jan 4 2021; 59: 92-99
        • van der Kaaij R.T.
        • de Rooij M.V.
        • van Coevorden F.
        • et al.
        Using textbook outcome as a measure of quality of care in oesophagogastric cancer surgery.
        Br J Surg. 2018; 105 (Apr): 561-569
        • Kolfschoten N.E.
        • Kievit J.
        • Gooiker G.A.
        • et al.
        Focusing on desired outcomes of care after colon cancer resections; hospital variations in 'textbook outcome.
        Eur J Surg Oncol. 2013; 39 (. Feb): 156-163
        • Wiseman J.T.
        • Ethun C.G.
        • Cloyd J.M.
        • et al.
        Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: a multi-institutional analysis of the US Sarcoma Collaborative.
        J Surg Oncol. 2020; 122 (Nov): 1189-1198
        • Lazarides A.L.
        • Cerullo M.
        • Moris D.
        • Brigman B.E.
        • Blazer D.G.
        • Eward W.C.
        Defining a textbook surgical outcome for patients undergoing surgical resection of intermediate and high-grade soft tissue sarcomas of the extremities.
        J Surg Oncol. Oct 2020; 122: 884-896
        • Moris D.
        • Cerullo M.
        • Nussbaum D.P.
        • Blazer 3rd, D.G.
        Textbook outcomes among patients undergoing retroperitoneal sarcoma resection.
        Anticancer Res. 2020; 40 (Apr): 2107-2115
        • Trojani M.
        • Contesso G.
        • Coindre J.M.
        • et al.
        Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system.
        Int J Cancer. Jan 15. 1984; 33: 37-42
        • Miettinen M.
        • Lasota J.
        Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
        Arch Pathol Lab Med. 2006; 130 (Oct): 1466-1478
        • Clavien P.A.
        • Barkun J.
        • de Oliveira M.L.
        • et al.
        The Clavien-Dindo classification of surgical complications: five-year experience.
        Ann Surg. 2009; 250 (Aug): 187-196
        • Nakamura K.
        • Nakamura T.
        • Iino T.
        • et al.
        Expression of interleukin-6 and the interleukin-6 receptor predicts the clinical outcomes of patients with soft tissue sarcomas.
        Cancers. 2020; 12 (Mar 3): 585
        • Ruka W.
        • Rutkowski P.
        • Kaminska J.
        • Rysinska A.
        • Steffen J.
        Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance.
        Ann Oncol. 2001; 12 (Oct): 1423-1432
        • Nakamura T.
        • Matsumine A.
        • Matsubara T.
        • Asanuma K.
        • Uchida A.
        • Sudo A.
        The combined use of the neutrophil-lymphocyte ratio and C-reactive protein level as prognostic predictors in adult patients with soft tissue sarcoma.
        J Surg Oncol. 2013; 108 (Dec): 481-485
        • Szkandera J.
        • Absenger G.
        • Liegl-Atzwanger B.
        • et al.
        Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients.
        Br J Cancer. Apr 30 2013; 108: 1677-1683
        • Choi E.S.
        • Kim H.S.
        • Han I.
        Elevated preoperative systemic inflammatory markers predict poor outcome in localized soft tissue sarcoma.
        Ann Surg Oncol. 2014; 21 (Mar): 778-785
        • Que Y.
        • Qiu H.
        • Li Y.
        • et al.
        Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma.
        BMC Cancer. Oct 2 2015; 15: 648
        • Liu G.
        • Ke L.C.
        • Sun S.R.
        Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: a meta-analysis.
        Medicine (Baltimore). 2018; 97 (Sep)e12176
        • Viñal D.
        • Martinez D.
        • Garcia-Cuesta J.A.
        • et al.
        Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas.
        Clin Transl Oncol. Oct 2020; 22: 1849-1856
        • Griffiths T.T.
        • Arango M.W.F.
        • Smith I.M.
        • Wade R.G.
        The baseline neutrophil lymphocyte ratio predicts survival in soft-tissue sarcoma: a 17-year cohort study.
        J Plast Reconstr Aesthetic Surg. 2022; 75 (Apr): 1372-1379
        • Fisher D.T.
        • Appenheimer M.M.
        • Evans S.S.
        The two faces of IL-6 in the tumor microenvironment.
        Semin Immunol. 2014; 26 (Feb): 38-47
        • Guthrie G.J.
        • Roxburgh C.S.
        • Horgan P.G.
        • McMillan D.C.
        Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer?.
        Cancer Treat Rev. 2013; 39 (Feb): 89-96
        • Lippitz B.E.
        • Harris R.A.
        Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis.
        OncoImmunology. May 2016; 5e1093722
        • Plas M.
        • Rutgers A.
        • van der Wal-Huisman H.
        • et al.
        The association between the inflammatory response to surgery and postoperative complications in older patients with cancer; a prospective prognostic factor study.
        J Geriatr Oncol. 2020; 11 (Jun): 873-879
        • Trepanier M.
        • Minnella E.M.
        • Paradis T.
        • et al.
        Improved disease-free survival after prehabilitation for colorectal cancer surgery.
        Ann Surg. 2019; 270 (Sep): 493-501
        • Heger P.
        • Probst P.
        • Wiskemann J.
        • Steindorf K.
        • Diener M.K.
        • Mihaljevic A.L.
        A systematic review and meta-analysis of physical exercise prehabilitation in major abdominal surgery (PROSPERO 2017 CRD42017080366).
        J Gastrointest Surg. 2020; 24 (Jun): 1375-1385
        • Shen J.
        • Dai S.
        • Li Z.
        • et al.
        Effect of enteral immunonutrition in patients undergoing surgery for gastrointestinal cancer: an updated systematic review and meta-analysis.
        Front Nutr. 2022; 9941975
        • Wang A.S.
        • Armstrong E.J.
        • Armstrong A.W.
        Corticosteroids and wound healing: clinical considerations in the perioperative period.
        Am J Surg. 2013; 206 (Sep): 410-417
        • Nishimoto N.
        • Terao K.
        • Mima T.
        • Nakahara H.
        • Takagi N.
        • Kakehi T.
        Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
        Blood. Nov 15. 2008; 112: 3959-3964
        • Salama C.
        • Han J.
        • Yau L.
        • et al.
        Tocilizumab in patients hospitalized with covid-19 pneumonia.
        N Engl J Med. Jan 7 2021; 384: 20-30
        • Dijkgraaf E.M.
        • Santegoets S.J.
        • Reyners A.K.
        • et al.
        A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer.
        Ann Oncol. Oct 2015; 26: 2141-2149